1 / 28

Arvind Raghavan, Ph.D., Vice President, Business Development

Innovative Nanostructures for Cancer Treatment. Arvind Raghavan, Ph.D., Vice President, Business Development. Who we are. Seed-stage biotech start-up University of MN technology Targeted therapeutic & diagnostic platform for a wide range of diseases.

blenda
Télécharger la présentation

Arvind Raghavan, Ph.D., Vice President, Business Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Innovative Nanostructures for Cancer Treatment Arvind Raghavan, Ph.D., Vice President, Business Development

  2. Who we are • Seed-stage biotech start-up • University of MN technology • Targeted therapeutic & diagnostic platform for a wide range of diseases. • Our mission is to improve human health by enabling individualized patient treatments for optimal patient outcomes.

  3. The Devastation of Cancer 241,200 Diagnosed 28,000 Deaths 290,000 Diagnosed 39,500 Deaths Source: American Cancer Society, 2012

  4. Conventional Cancer Treatments

  5. From the old…to the new • Emphasis away from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs. • Shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials. • Treatment selection driven by understanding the genetics and biology of the cancer AND the patient.

  6. From the old…to the new Emphasis away from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs.

  7. From the old…to the new • Emphasis away from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs. • Shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials. • Treatment selection driven by understanding the genetics and biology of the cancer AND the patient.

  8. From the old…to the new Treatment selection driven by understanding the genetics and biology of the cancer AND the patient. Arrays, PCR, PCR, Arrays, Chemo + Imaging Imaging + mAb Combo mAbs Combo Chemo

  9. Targeted Drugs • By harnessing antibodies to deliver toxic payloads to cancer cells, while largely sparing healthy cells, the drugs are a step toward the “magic bullets” against cancer first envisioned by Paul Ehrlich, a German Nobel laureate, about 100 years ago. • Published: May 31, 2012 “I’m able to live a normal life,” said Saitowitz, 47, a mother of two young children. “I haven’t lost any of my hair.”

  10. How targeted drugs work • Antibody-drug conjugate (Adcetris; Seattle Genetics) http://www.adcetris.com/hcp/

  11. Tychon’s technology Chemically Self-Assembled Nanostructures (CSANs) Targeting Signal + Payload Bio-functionalized Components Dimerizer Monomer CSANs Multimer Dimer

  12. Tychon’s technology Chemically Self-Assembled Nanostructures (CSANs) Targeting Signal + Payload Bio-functionalized Components Dimerizer + CSANs Multimer Dimer

  13. Tychon’s technology Chemically Self-Assembled Nanostructures (CSANs) Specifically targets cancer cells, sparing normal cells Targeting protein Imaging agent or Drug

  14. Tychon’s technology

  15. Tychon’s technology CSAN Imaging agent Identifies cancer cell

  16. Tychon’s technology CSAN Therapeutic agent Enters cancer cell Kills cancer cell

  17. Partnership Business Model

  18. Product Pipeline 2013 2016 2015 2014 2018 2017 Prostate Imaging $ $ $ Breast Imaging $ $ Prostate Therapeutic $ $ Breast Therapeutic $ $ Pancreatic Therapeutic $

  19. . . . for cancer and autoimmune diseases that are engineered to hit two or more targets on cells instead of just one. In exchange for helping Merck create these so-called “bispecific” antibodies, Zymeworks is getting . . . . . . the Zymeworks deal represents a chance for Merck to move into a hot area of protein drug engineering that biotech leaders like Genentech, Amgen, and Biogen Idec have been pursuing for years.

  20. Targeted Drugs “Pfizer is applying this ‘precision medicine’ strategy to diabetes, inflammation and other diseases aside from cancer, and aims by 2015 to have 50% of all its experimental drugs in human testing use the approach.” - Mikael Dolsten, Pfizer's R&D chief

  21. Individualized treatment for improved quality of life.

  22. OurCore Team Brian R. White, Ph.D. Head, R & D Mark S. Robbins, Ph.D., J.D. President & CEO ArvindRaghavan, Ph.D. VP, Business Dev Carston R. Wagner, Ph.D., CSO, Inventor, U of MN

  23. Accomplishments Division Finalist in MN Cup. Strong Business & Scientific Advisory Boards. Ongoing partnership talks with five biotech companies. Presented at 2012 Life Science Venture Summit. Strong validation by Review Panel on SBIR proposals. Grant award to Dr. Wagner from CPD.

  24. Innovative Nanostructures for Cancer Treatment Arvind Raghavan, Ph.D., Vice President, Business Development

More Related